个人中心 - 老虎社区

patrickLai

IP属地：未知

帖子 · 36帖子 · 36
关注 · 0关注 · 0
粉丝 · 0粉丝 · 0

- patrickLaipatrickLai
  ·2021-12-28
  Good
  Will Hey Dude Help Crocs Reach $5 Billion in Sales by 2026?
  Crocs made its largest acquisition to date last week when it inked a deal to acquire the privately-o
  Will Hey Dude Help Crocs Reach $5 Billion in Sales by 2026?
  2,482 评论
  1
  分享
  举报
- patrickLaipatrickLai
  ·2021-12-27
  Big movement
  非常抱歉，此主贴已删除
  1,828 评论
  3
  分享
  举报
- patrickLaipatrickLai
  ·2021-12-25
  Good
  非常抱歉，此主贴已删除
  2,868 评论
  3
  分享
  举报
- patrickLaipatrickLai
  ·2021-12-24
  Good
  非常抱歉，此主贴已删除
  2,706 评论
  3
  分享
  举报
- patrickLaipatrickLai
  ·2021-12-22
  Huat ah
  非常抱歉，此主贴已删除
  2,865 1
  5
  分享
  举报
- patrickLaipatrickLai
  ·2021-12-19
  Like like
  Novavax, Vir among healthcare gainers, Pfizer posts best rally in a decade
  The healthcare stocks in the S&P 500 outperformed all other sectors in the broader index with a ~2.5
  Novavax, Vir among healthcare gainers, Pfizer posts best rally in a decade
  1,757 1
  4
  分享
  举报
- patrickLaipatrickLai
  ·2021-12-18
  Yeah
  Cerner Shares Surge On Reports Of $30 Billion Oracle Takeover Bid
  Cerner Corp. -Get Cerner Corporation Report shares surged Friday after the Wall Street Journal repor
  Cerner Shares Surge On Reports Of $30 Billion Oracle Takeover Bid
  2,272 1
  5
  分享
  举报
- patrickLaipatrickLai
  ·2021-12-15
  Nice
  非常抱歉，此主贴已删除
  2,529 2
  6
  分享
  举报
- patrickLaipatrickLai
  ·2021-12-12
  Good
  非常抱歉，此主贴已删除
  2,551 1
  3
  分享
  举报
- patrickLaipatrickLai
  ·2021-12-11
  [Grin]
  非常抱歉，此主贴已删除
  2,370 评论
  3
  分享
  举报
暂无粉丝

热议股票

{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"3585604372962377","uuid":"3585604372962377","gmtCreate":1622512789390,"gmtModify":1638170490735,"name":"patrickLai","pinyin":"patricklai","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/baedd77ad7c3a28da1ae2ecc8b2e88aa","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":8,"headSize":10,"tweetSize":36,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"35ec162348d5460f88c959321e554969-2","templateUuid":"35ec162348d5460f88c959321e554969","name":"宗师交易员","description":"证券或期货账户累计交易次数达到100次","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.01.02","exceedPercentage":"80.58%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.11.04","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.10.15","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":4,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":696601923,"gmtCreate":1640674012432,"gmtModify":1640674012552,"author":{"id":"3585604372962377","authorId":"3585604372962377","name":"patrickLai","avatar":"https://static.tigerbbs.com/baedd77ad7c3a28da1ae2ecc8b2e88aa","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585604372962377","authorIdStr":"3585604372962377"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/696601923","repostId":"1120855192","repostType":4,"repost":{"id":"1120855192","kind":"news","pubTimestamp":1640668339,"share":"https://www.laohu8.com/m/news/1120855192?lang=&edition=full","pubTime":"2021-12-28 13:12","market":"us","language":"en","title":"Will Hey Dude Help Crocs Reach $5 Billion in Sales by 2026?","url":"https://stock-news.laohu8.com/highlight/detail?id=1120855192","media":"Footwear News","summary":"Crocs made its largest acquisition to date last week when it inked a deal to acquire the privately-o","content":"<p>Crocs made its largest acquisition to date last week when it&nbsp;inked a deal&nbsp;to acquire the privately-owned footwear brand Hey Dude.</p>\n<p>The deal is valued at $2.5 billion and expected to close in Q1 of 2022. While Hey Dude is privately owned, Crocs pointed out the company’s impressive growth in revenue and profits in recent years. 43% of Hey Dude’s sales are currently online and the brand projects $570 million in revenue in 2021.</p>\n<p>Crocs is confident that Hey Dude will help contribute to its recent revenue growth and align with its previously stated goal to help Crocs achieve$5 billion in sales by 2026.Crocs plans to make Hey Dude a $1 billion brand by 2024.</p>\n<p>While executives seemed confident in achieving these goals, investors initially appeared more hesitant. In the wake of the announcement on Thursday, shares of Crocs dropped close to 12%, suggesting concern and uneasiness.</p>\n<p>However, some analysts eased investor fear and projected strong results from the acquisition.</p>\n<p>Williams Trading analyst Sam Poser said in a recent note that despite the reactive stock drop, the deal “will prove very accretive” to Crocs. He attributed the initial stock drop to a general investor unawareness for the Hey Dude Brand, which he said has grown revenue at a 20% rate over the last few years and is still gaining momentum.</p>\n<p>“Retailers are more knowledgeable of trends than the very large majority of the&nbsp;investment community is,” Poser wrote. “Crocs trends remain strong, and management remains&nbsp;confident that sales will reach $5 billion by 2026.”</p>\n<p>Baird analyst Jonathan Komp also pointed out Hey Dude’s trajectory of rapid growth, highlighting how the company is estimated to have grown&nbsp;revenue twofold in 2021, despite supply chain issues. The brand is projected to hit $700 to $750 million in revenue in 2022.</p>\n<p>Crocs acquired Jibbitz, the company that makes accessories for the&nbsp;clogs, in 2006. Its most recent acquisition initiates the company’s transition from single-brand to multi-brand.Once under the Crocs banner, Hey Dude will still operate independently with Hey Dude founder Alessandro Rosano as strategic advisor and creative director. Former CCM Hockey CEO Rick Blackshaw has been tapped as Hey Dude’s new EVP and brand president.</p>\n<p>“In upcoming quarters, we are optimistic that Crocs can prove continued strong execution as the company has as a mono-brand operator, which should reinforce investor confidence in the growth outlook and support higher valuation over time,” Komp wrote.</p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Will Hey Dude Help Crocs Reach $5 Billion in Sales by 2026?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWill Hey Dude Help Crocs Reach $5 Billion in Sales by 2026?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-28 13:12 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/hey-dude-help-crocs-reach-190853070.html><strong>Footwear News</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Crocs made its largest acquisition to date last week when it inked a deal to acquire the privately-owned footwear brand Hey Dude.\nThe deal is valued at $2.5 billion and expected to close in Q1 of 2022...</p>\n\n<a href=\"https://finance.yahoo.com/news/hey-dude-help-crocs-reach-190853070.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CROX":"卡骆驰"},"source_url":"https://finance.yahoo.com/news/hey-dude-help-crocs-reach-190853070.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1120855192","content_text":"Crocs made its largest acquisition to date last week when it inked a deal to acquire the privately-owned footwear brand Hey Dude.\nThe deal is valued at $2.5 billion and expected to close in Q1 of 2022. While Hey Dude is privately owned, Crocs pointed out the company’s impressive growth in revenue and profits in recent years. 43% of Hey Dude’s sales are currently online and the brand projects $570 million in revenue in 2021.\nCrocs is confident that Hey Dude will help contribute to its recent revenue growth and align with its previously stated goal to help Crocs achieve$5 billion in sales by 2026.Crocs plans to make Hey Dude a $1 billion brand by 2024.\nWhile executives seemed confident in achieving these goals, investors initially appeared more hesitant. In the wake of the announcement on Thursday, shares of Crocs dropped close to 12%, suggesting concern and uneasiness.\nHowever, some analysts eased investor fear and projected strong results from the acquisition.\nWilliams Trading analyst Sam Poser said in a recent note that despite the reactive stock drop, the deal “will prove very accretive” to Crocs. He attributed the initial stock drop to a general investor unawareness for the Hey Dude Brand, which he said has grown revenue at a 20% rate over the last few years and is still gaining momentum.\n“Retailers are more knowledgeable of trends than the very large majority of the investment community is,” Poser wrote. “Crocs trends remain strong, and management remains confident that sales will reach $5 billion by 2026.”\nBaird analyst Jonathan Komp also pointed out Hey Dude’s trajectory of rapid growth, highlighting how the company is estimated to have grown revenue twofold in 2021, despite supply chain issues. The brand is projected to hit $700 to $750 million in revenue in 2022.\nCrocs acquired Jibbitz, the company that makes accessories for the clogs, in 2006. Its most recent acquisition initiates the company’s transition from single-brand to multi-brand.Once under the Crocs banner, Hey Dude will still operate independently with Hey Dude founder Alessandro Rosano as strategic advisor and creative director. Former CCM Hockey CEO Rick Blackshaw has been tapped as Hey Dude’s new EVP and brand president.\n“In upcoming quarters, we are optimistic that Crocs can prove continued strong execution as the company has as a mono-brand operator, which should reinforce investor confidence in the growth outlook and support higher valuation over time,” Komp wrote.","news_type":1,"symbols_score_info":{"CROX":0.9}},"isVote":1,"tweetType":1,"viewCount":2482,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":696046575,"gmtCreate":1640584273394,"gmtModify":1640584273568,"author":{"id":"3585604372962377","authorId":"3585604372962377","name":"patrickLai","avatar":"https://static.tigerbbs.com/baedd77ad7c3a28da1ae2ecc8b2e88aa","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585604372962377","authorIdStr":"3585604372962377"},"themes":[],"htmlText":"Big movement","listText":"Big movement","text":"Big movement","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/696046575","repostId":"1122841396","repostType":4,"isVote":1,"tweetType":1,"viewCount":1828,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698257535,"gmtCreate":1640419284637,"gmtModify":1640419284792,"author":{"id":"3585604372962377","authorId":"3585604372962377","name":"patrickLai","avatar":"https://static.tigerbbs.com/baedd77ad7c3a28da1ae2ecc8b2e88aa","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585604372962377","authorIdStr":"3585604372962377"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/698257535","repostId":"2193917819","repostType":4,"isVote":1,"tweetType":1,"viewCount":2868,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698143823,"gmtCreate":1640326004272,"gmtModify":1640326004425,"author":{"id":"3585604372962377","authorId":"3585604372962377","name":"patrickLai","avatar":"https://static.tigerbbs.com/baedd77ad7c3a28da1ae2ecc8b2e88aa","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585604372962377","authorIdStr":"3585604372962377"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/698143823","repostId":"1105843279","repostType":4,"isVote":1,"tweetType":1,"viewCount":2706,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691165420,"gmtCreate":1640151523703,"gmtModify":1640151523844,"author":{"id":"3585604372962377","authorId":"3585604372962377","name":"patrickLai","avatar":"https://static.tigerbbs.com/baedd77ad7c3a28da1ae2ecc8b2e88aa","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585604372962377","authorIdStr":"3585604372962377"},"themes":[],"htmlText":"Huat ah","listText":"Huat ah","text":"Huat ah","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/691165420","repostId":"1130693665","repostType":4,"isVote":1,"tweetType":1,"viewCount":2865,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":693093938,"gmtCreate":1639921078798,"gmtModify":1639921078935,"author":{"id":"3585604372962377","authorId":"3585604372962377","name":"patrickLai","avatar":"https://static.tigerbbs.com/baedd77ad7c3a28da1ae2ecc8b2e88aa","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585604372962377","authorIdStr":"3585604372962377"},"themes":[],"htmlText":"Like like","listText":"Like like","text":"Like like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/693093938","repostId":"1122414343","repostType":4,"repost":{"id":"1122414343","kind":"news","pubTimestamp":1639884070,"share":"https://www.laohu8.com/m/news/1122414343?lang=&edition=full","pubTime":"2021-12-19 11:21","market":"us","language":"en","title":"Novavax, Vir among healthcare gainers, Pfizer posts best rally in a decade","url":"https://stock-news.laohu8.com/highlight/detail?id=1122414343","media":"Seeking Alpha","summary":"The healthcare stocks in the S&P 500 outperformed all other sectors in the broader index with a ~2.5","content":"<p>The healthcare stocks in the S&amp;P 500 outperformed all other sectors in the broader index with a ~2.5% gain thanks mainly to M&amp;A prospects. <a href=\"https://laohu8.com/S/HCSG\">Healthcare</a> technology, along with names battling the resurgence of COVID-19, led the gainers while the overall index fell ~1.9%.</p>\n<p>Among stocks with more than $2B market capitalization and 100K average daily volume over the past week, <a href=\"https://laohu8.com/S/ARNA\">Arena Pharmaceuticals </a> dominated with a ~83.8% rise after <a href=\"https://laohu8.com/S/PFE\">Pfizer </a> agreed to acquire it in a ~$6.7B deal with 100% premium for the biotech. <a href=\"https://laohu8.com/S/CERN\">Cerner </a> also joined the M&amp;A-driven rally to gain ~20.7% over the week amid reports of a potential ~$30B bid from <a href=\"https://laohu8.com/S/ORCL\">Oracle </a> for the electronic-medical-records company.</p>\n<p>Vaccine developer, <a href=\"https://laohu8.com/S/NVAX\">Novavax </a> jumped ~30.5% as investors welcomed the WHO clearance for the company’s COVID-19 shot. Further gains for the Maryland-based biotech are likely when an expert panel of the European regulators is set to review the marketing authorization for the vaccine next week.</p>\n<p><a href=\"https://laohu8.com/S/BHVN\">Biohaven Pharmaceutical </a> posted a ~25.2% weekly rise after the company announced the approval for NURTEC ODT (rimegepant) in Israel, making it the first regulatory win for the migraine drug outside the U.S. Meanwhile, Vir Biotechnology (NASDAQ:VIR) surged ~23.7% to stand among best gainers for the second week this month. More data emerged this week confirming the Omicron-neutralizing effect of the company’s COVID-19 therapy developed in partnership with GlaxoSmithKline (NYSE:GSK). Rounding out the top five gainers, <a href=\"https://laohu8.com/S/ROIV\">Roivant Sciences </a> added ~22.6%.</p>\n<p>Notable gainer: <a href=\"https://laohu8.com/S/PFE\">Pfizer</a> (PFE) made headlines throughout the week, raising its sales guidance for the COVID-19 vaccine once again as the rapidly spreading Omicron variant highlighted the need for booster shots. Despite an abrupt end to its six-day rally on Friday, the <a href=\"https://laohu8.com/S/NWY\">New York</a>-based pharma giant with a ~12.7% rise recorded its best weekly gain since March 2009.</p>\n<p>Among worst performers of the week, two newly IPO’ed biotechs, Instil Bio (NASDAQ:TIL) and Exscientia (NASDAQ:EXAI), stood out, falling 19.3% and ~13.5%, respectively, despite their favorable ratings on Wall Street. Meanwhile, GoodRx Holdings (NASDAQ:GDRX), an operator of a price comparison platform for prescription medicine slumped ~15.6%.</p>\n<p>Last week’s best performer, <a href=\"https://laohu8.com/S/BHG\">Bright Health Group</a>, crashed ~13.1%, hurt by the sole Sell rating issued by <a href=\"https://laohu8.com/S/GS\">Goldman Sachs</a> even as the investment bank kicked off its coverage on managed care with largely positive views.</p>\n<p>Allogene Therapeutics (NASDAQ:ALLO) dropped ~12.3% after the company’s ASH presentations on Phase 1 data for experimental allogeneic <a href=\"https://laohu8.com/S/00699\">CAR</a> T therapies failed to excite investors, including Cathie Wood’s Ark Investment Management, which sold ~1.6M shares of the biotech several days later.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax, Vir among healthcare gainers, Pfizer posts best rally in a decade</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax, Vir among healthcare gainers, Pfizer posts best rally in a decade\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-19 11:21 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3781487-novavax-vir-among-healthcare-gainers-pfizer-posts-best-rally-in-a-decade><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The healthcare stocks in the S&P 500 outperformed all other sectors in the broader index with a ~2.5% gain thanks mainly to M&A prospects. Healthcare technology, along with names battling the ...</p>\n\n<a href=\"https://seekingalpha.com/news/3781487-novavax-vir-among-healthcare-gainers-pfizer-posts-best-rally-in-a-decade\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4533":"AQR资本管理(全球第二大对冲基金)","ARNA":"阿里那","BK4007":"制药","ORCL":"甲骨文","BK4568":"美国抗疫概念","BK4550":"红杉资本持仓","CERN":"美国塞纳","BK4534":"瑞士信贷持仓","PFE":"辉瑞"},"source_url":"https://seekingalpha.com/news/3781487-novavax-vir-among-healthcare-gainers-pfizer-posts-best-rally-in-a-decade","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1122414343","content_text":"The healthcare stocks in the S&P 500 outperformed all other sectors in the broader index with a ~2.5% gain thanks mainly to M&A prospects. Healthcare technology, along with names battling the resurgence of COVID-19, led the gainers while the overall index fell ~1.9%.\nAmong stocks with more than $2B market capitalization and 100K average daily volume over the past week, Arena Pharmaceuticals  dominated with a ~83.8% rise after Pfizer  agreed to acquire it in a ~$6.7B deal with 100% premium for the biotech. Cerner  also joined the M&A-driven rally to gain ~20.7% over the week amid reports of a potential ~$30B bid from Oracle  for the electronic-medical-records company.\nVaccine developer, Novavax  jumped ~30.5% as investors welcomed the WHO clearance for the company’s COVID-19 shot. Further gains for the Maryland-based biotech are likely when an expert panel of the European regulators is set to review the marketing authorization for the vaccine next week.\nBiohaven Pharmaceutical  posted a ~25.2% weekly rise after the company announced the approval for NURTEC ODT (rimegepant) in Israel, making it the first regulatory win for the migraine drug outside the U.S. Meanwhile, Vir Biotechnology (NASDAQ:VIR) surged ~23.7% to stand among best gainers for the second week this month. More data emerged this week confirming the Omicron-neutralizing effect of the company’s COVID-19 therapy developed in partnership with GlaxoSmithKline (NYSE:GSK). Rounding out the top five gainers, Roivant Sciences  added ~22.6%.\nNotable gainer: Pfizer (PFE) made headlines throughout the week, raising its sales guidance for the COVID-19 vaccine once again as the rapidly spreading Omicron variant highlighted the need for booster shots. Despite an abrupt end to its six-day rally on Friday, the New York-based pharma giant with a ~12.7% rise recorded its best weekly gain since March 2009.\nAmong worst performers of the week, two newly IPO’ed biotechs, Instil Bio (NASDAQ:TIL) and Exscientia (NASDAQ:EXAI), stood out, falling 19.3% and ~13.5%, respectively, despite their favorable ratings on Wall Street. Meanwhile, GoodRx Holdings (NASDAQ:GDRX), an operator of a price comparison platform for prescription medicine slumped ~15.6%.\nLast week’s best performer, Bright Health Group, crashed ~13.1%, hurt by the sole Sell rating issued by Goldman Sachs even as the investment bank kicked off its coverage on managed care with largely positive views.\nAllogene Therapeutics (NASDAQ:ALLO) dropped ~12.3% after the company’s ASH presentations on Phase 1 data for experimental allogeneic CAR T therapies failed to excite investors, including Cathie Wood’s Ark Investment Management, which sold ~1.6M shares of the biotech several days later.","news_type":1,"symbols_score_info":{"ARNA":0.9,"CERN":0.9,"ORCL":0.9,"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":1757,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":699282422,"gmtCreate":1639811267512,"gmtModify":1639811267624,"author":{"id":"3585604372962377","authorId":"3585604372962377","name":"patrickLai","avatar":"https://static.tigerbbs.com/baedd77ad7c3a28da1ae2ecc8b2e88aa","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585604372962377","authorIdStr":"3585604372962377"},"themes":[],"htmlText":"Yeah","listText":"Yeah","text":"Yeah","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/699282422","repostId":"1106862392","repostType":4,"repost":{"id":"1106862392","kind":"news","pubTimestamp":1639810154,"share":"https://www.laohu8.com/m/news/1106862392?lang=&edition=full","pubTime":"2021-12-18 14:49","market":"us","language":"en","title":"Cerner Shares Surge On Reports Of $30 Billion Oracle Takeover Bid","url":"https://stock-news.laohu8.com/highlight/detail?id=1106862392","media":"The Street","summary":"Cerner Corp. -Get Cerner Corporation Report shares surged Friday after the Wall Street Journal repor","content":"<p><a href=\"https://laohu8.com/S/CERN\">Cerner Corp.</a> -Get Cerner Corporation Report&nbsp;shares surged Friday after the Wall Street Journal reported that <a href=\"https://laohu8.com/S/ORCL\">Oracle&nbsp;</a> -Get Oracle Corporation Report&nbsp;is preparing to buy the electronic medical records company in a deal worth as much as $30 billion.</p>\n<p>A takeover of Cerner, the biggest designer of software used by doctors and hospitals to mange and store medical records, would not only be one of the biggest M&amp;A deals of the year, it would also be the biggest in Oracle's corporate history -- more than 3 times the size of its $10 billion purchase of PeopleSoft in 2005 -- and a bold statement from CEO Safra Catz, who assumed sole control of the cloud and software group in 2019.</p>\n<p>Cerner, which posted third quarter revenues of $1.468 billion in October,&nbsp;has a 25% share of the medical records market, according to SVB Leerrink.</p>\n<p>\"We view the potential deal as a positive for CERN as it will allow the company to undergo its transition from an EHR to a healthcare platform within the cover of a far larger organization, and with the benefit of a premium takeout valuation,\" said Leerink analysts Stephanie Davis. \"We are cautious on potential pushback from Oracle shareholders creating risk to a deal announcement, as the deal would mark a transition away from the company’s core organic growth acceleration story while the check size implies likely dilution to holders.\"</p>\n<p>Cerner shares ended up $10.28, or 12.9%, at $89.77. Oracle shares fell $6.60, or, 6.4%, to $96.62.</p>\n<p><img src=\"https://static.tigerbbs.com/22804ede647ca4b70ab697475b6acc79\" tg-width=\"966\" tg-height=\"636\" referrerpolicy=\"no-referrer\"></p>\n<p>Oracle shares traded at an all-time high last week, giving the cloud and software group a market value of around $290 billion, following&nbsp;better-than-expected second quarter earnings and a robust near-term outlook.</p>\n<p>Oracle, which earns the bulk of its revenues from its cloud services and license support unit, beat Street earnings forecasts by a dime with an adjusted second quarter bottom line of $1.12 per share.</p>\n<p>Cloud division revenues topped $7.5 billion as companies continue to spend on hybrid work solutions in a post-pandemic world, while overall revenues grew by 6% to $10.4 billon.</p>\n<p>Bookings grew at an even faster pace, rising 11% from last year's levels, giving Oracle the confidence to forecast current quarter revenues in the region of $10.7 billion to $10.9 billion, based on growth forecasts, with profits of between $1.19 and $1.23 per share.</p>","source":"lsy1610613172068","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cerner Shares Surge On Reports Of $30 Billion Oracle Takeover Bid</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCerner Shares Surge On Reports Of $30 Billion Oracle Takeover Bid\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-18 14:49 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/markets/cerner-shares-surge-on-reports-of-30-billion-oracle-takeover-bid><strong>The Street</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Cerner Corp. -Get Cerner Corporation Report shares surged Friday after the Wall Street Journal reported that Oracle  -Get Oracle Corporation Report is preparing to buy the electronic medical records ...</p>\n\n<a href=\"https://www.thestreet.com/markets/cerner-shares-surge-on-reports-of-30-billion-oracle-takeover-bid\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ORCL":"甲骨文","CERN":"美国塞纳"},"source_url":"https://www.thestreet.com/markets/cerner-shares-surge-on-reports-of-30-billion-oracle-takeover-bid","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1106862392","content_text":"Cerner Corp. -Get Cerner Corporation Report shares surged Friday after the Wall Street Journal reported that Oracle  -Get Oracle Corporation Report is preparing to buy the electronic medical records company in a deal worth as much as $30 billion.\nA takeover of Cerner, the biggest designer of software used by doctors and hospitals to mange and store medical records, would not only be one of the biggest M&A deals of the year, it would also be the biggest in Oracle's corporate history -- more than 3 times the size of its $10 billion purchase of PeopleSoft in 2005 -- and a bold statement from CEO Safra Catz, who assumed sole control of the cloud and software group in 2019.\nCerner, which posted third quarter revenues of $1.468 billion in October, has a 25% share of the medical records market, according to SVB Leerrink.\n\"We view the potential deal as a positive for CERN as it will allow the company to undergo its transition from an EHR to a healthcare platform within the cover of a far larger organization, and with the benefit of a premium takeout valuation,\" said Leerink analysts Stephanie Davis. \"We are cautious on potential pushback from Oracle shareholders creating risk to a deal announcement, as the deal would mark a transition away from the company’s core organic growth acceleration story while the check size implies likely dilution to holders.\"\nCerner shares ended up $10.28, or 12.9%, at $89.77. Oracle shares fell $6.60, or, 6.4%, to $96.62.\n\nOracle shares traded at an all-time high last week, giving the cloud and software group a market value of around $290 billion, following better-than-expected second quarter earnings and a robust near-term outlook.\nOracle, which earns the bulk of its revenues from its cloud services and license support unit, beat Street earnings forecasts by a dime with an adjusted second quarter bottom line of $1.12 per share.\nCloud division revenues topped $7.5 billion as companies continue to spend on hybrid work solutions in a post-pandemic world, while overall revenues grew by 6% to $10.4 billon.\nBookings grew at an even faster pace, rising 11% from last year's levels, giving Oracle the confidence to forecast current quarter revenues in the region of $10.7 billion to $10.9 billion, based on growth forecasts, with profits of between $1.19 and $1.23 per share.","news_type":1,"symbols_score_info":{"CERN":0.9,"ORCL":0.9}},"isVote":1,"tweetType":1,"viewCount":2272,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":607688637,"gmtCreate":1639532977052,"gmtModify":1639533012079,"author":{"id":"3585604372962377","authorId":"3585604372962377","name":"patrickLai","avatar":"https://static.tigerbbs.com/baedd77ad7c3a28da1ae2ecc8b2e88aa","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585604372962377","authorIdStr":"3585604372962377"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/607688637","repostId":"2191602753","repostType":4,"isVote":1,"tweetType":1,"viewCount":2529,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":604088394,"gmtCreate":1639281362231,"gmtModify":1639281362356,"author":{"id":"3585604372962377","authorId":"3585604372962377","name":"patrickLai","avatar":"https://static.tigerbbs.com/baedd77ad7c3a28da1ae2ecc8b2e88aa","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585604372962377","authorIdStr":"3585604372962377"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/604088394","repostId":"2190567199","repostType":4,"isVote":1,"tweetType":1,"viewCount":2551,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":605513574,"gmtCreate":1639189549315,"gmtModify":1639190159144,"author":{"id":"3585604372962377","authorId":"3585604372962377","name":"patrickLai","avatar":"https://static.tigerbbs.com/baedd77ad7c3a28da1ae2ecc8b2e88aa","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585604372962377","authorIdStr":"3585604372962377"},"themes":[],"htmlText":"[Grin]&nbsp;","listText":"[Grin]&nbsp;","text":"[Grin]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/605513574","repostId":"2190673267","repostType":4,"isVote":1,"tweetType":1,"viewCount":2370,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"defaultTab":"followers","isTTM":false}